心通醫療-B(02160.HK)2024年度營收增長7.5%至3.616億元 虧損大幅收窄至5330萬元
格隆匯3月27日丨心通醫療-B(02160.HK)公佈年度業績,截至2024年12月31日止年度,集團收入為人民幣3.616億元,相比於截至2023年12月31日止年度的人民幣3.362億元增加了7.5%,主要是由於報吿期內,VitaFlow Liberty®及Alwide® Plus在全球商業化的持續推進,促進了TAVI產品的海外收入高速增長。此外,於報吿期內,我們的附屬公司上海佐心自主研發的AnchorMan®左心耳封堵系統及AnchorMan®左心耳導引系統在中國正式商業化,亦為集團帶來新增收入貢獻。
我們的毛利由截至2023年12月31日止年度的人民幣2.299億元增加9.3%至截至2024年12月31日止年度的人民幣2.512億元,同時毛利率由截至2023年12月31日止年度的68.4%增加1.1個百分點至截至2024年12月31日止年度的69.5%,主要是由於公司採取有效的降本控費措施,連同業務增長帶來的規模效應所致。
截至2024年12月31日止年度,集團錄得年內虧損人民幣5330萬元,而截至2023年12月31日止年度虧損為人民幣4.715億元。有關減少主要是由於(i)收入較去年增長7.5%,生產成本下降及毛利率上升;(ii)集團努力統籌內外部資源、發揮集中效應及提高運營效率,推動業務實現穩健增長;及(iii)集團轉回先前確認的對4C Medical股權投資的減值準備,並對持有的4C Medical發行的可轉換債券確認公允價值變動收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.